Dirk G. Brockstedt

SVP of Research and Development at Aduro BioTech. Dr. Brockstedt has more than 15 years experience in the fields of immunology and oncology originating with his PhD from Stanford University. At Cerus Corporation and Anza Therapeutics he developed attenuated and killed strains of Listeria monocytogenes as a therapeutic vaccine platform for the treatment of cancer and infectious disease. His experience covers the therapeutic use of genetically modified bacteria from bench to bedside, having led the development of bacterial therapeutics as Director of Immunology at Cerus Corporation through his current position. Prior to Cerus Corporation, Dr. Brockstedt spent 4 years at Aventis in the Immunotherapy and Anti-Angiogenesis group developing novel therapies against cancer. Dr. Brockstedt is the author of more than 20 peer-reviewed scientific articles and is a named inventor on 4 patents. His work is regularly published in high ranking journals including JCI, Infection and Immunity, Nature Medicine and PNAS.